Navigation Links
Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
Date:8/31/2007

SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the BioCentury NewsMakers Conference on Thursday, September 6, 2007 at 2:30 p.m. ET in New York, at the Thomas Weisel Healthcare Conference on Friday, September 7, 2007 at 9:10 a.m. ET in Boston and at the Bear Stearns Healthcare Conference on Monday, September 10, 2007 at 9:00 a.m. ET in New York. Daniel M. Bradbury, President and Chief Executive Officer of Amylin Pharmaceuticals, will be providing a corporate overview at BioCentury NewsMakers and Thomas Weisel. Mark G. Foletta, Senior Vice President, Finance and Chief Financial Officer of Amylin Pharmaceuticals, will be providing a corporate overview at Bear Stearns.

The live presentations and breakout sessions will be webcast, and recordings will be made available following the events. The webcasts and recordings will be accessible through Amylin's corporate website, located at http://www.amylin.com. To access the live webcasts, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is located in San Diego, California with over 1,700 employees nationwide. Further information on Amylin Pharmaceuticals and its pipeline in metabolism is available at http://www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/15/2017)... WARRINGTON, Pa. , Feb. 15, 2017 /PRNewswire/ ... ), a biotechnology company focused on developing aerosolized ... that it has completed a $10.5 million private ... expects that it has sufficient capital to fund ... 2b clinical trial data release in mid-2017. ...
(Date:2/15/2017)... , ... February 15, 2017 , ... ... will hold its sixth annual open house and technology show, Morris Madness, March ... live metal cutting demos from Okuma, Tsugami and Hardinge Group in addition to ...
(Date:2/15/2017)... 2017  Surrozen Inc., a newly formed biopharmaceutical company ... repair and regeneration of human tissues, has closed a ... Group, a science-driven venture capital firm based in ... used to implement a broad-based drug discovery platform aimed ... plays a central role in organism development, stem-cell maintenance ...
(Date:2/15/2017)... Group, a leading cosmetics company in China ... world, the company has successfully printed the skin of Asians ... to assure the smooth and reliable progress of the project, ... cell biology, pharmaceutical and regenerative medicine scientists from both ... After 98 experiments, the R&D team built the first Asian ...
Breaking Biology Technology:
(Date:1/24/2017)... Biopharm Reports has carried out a ... nuclear magnetic resonance spectroscopy (NMR). This involved the ... practices, developments, trends and end-user plans over the ... opportunities. These areas include growth in the use ... innovation requirements, hyphenated NMR techniques, main suppliers of ...
(Date:1/19/2017)... , January 19, 2017 According to a new ... and Forecast, 2014 - 2022," the global biometric sensor market is expected to ... to 2022. In 2015, Asia-Pacific dominated the global market ... private sectors. Continue Reading ... ...
(Date:1/13/2017)... 13, 2017 Sandata Technologies, LLC, a ... homecare industry, including Electronic Visit Verification™ (EVV™), announced ... Jugs, as Senior Vice President of Product Management. ... of homecare experience to Sandata, where he will ... to align Sandata,s suite of solutions with the ...
Breaking Biology News(10 mins):